Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
Invega Sustenna/Xeplion/Invega Trinza/Trevicta (paliperidone) Disease area(s): Psychiatry Manufacturer(s): Johnson & Johnson 2024 Sales (USD): $4.22 billion Why it sold so well: In 2024, J&Js long-acting antipsychotic portfolio including Invega Sustenna, Xeplion, Invega Trinza and Trevicta registered global sales of $4.22 billion, reflecting a 2.6% year-over-year increase
Lilleri et al, 2016), it is tempting to speculate that gp34 may be involved in this attenuation of humoral immunity
They support liver function, break down stored fat, and improve overall body composition
BPC-157 is typically framed as the more targeted, tissue-specific option in recovery research, while TB-500 is more often positioned as the broader systemic option tied to cell migration, tissue remodeling, and recovery support
US$ 22.03
US$ 21.66
US$ 28.50
.png)
US$ 27.02
US$ 28.05
